Experimental drug for advanced colorectal, esophageal, stomach, or ovarian cancer
Treatments studied
Part of Cancer clinical trials.
This study tests an experimental drug called IMC-R117C for people with certain advanced cancers. It aims to see if the drug can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific immune marker called HLA-A*02:01 (your doctor can check this with a blood test).
- You have advanced colorectal, esophageal, stomach, or ovarian cancer that has already been treated with standard therapies.
- You are able to do most daily activities on your own (ECOG 0 or 1).
- You do not have untreated or active cancer spread to the brain.
- You do not have a recent or ongoing bowel obstruction.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
This trial tests an experimental drug, IMC-P115C, for people with advanced cancers that have a specific marker called PRAME and a genetic type HLA-A*02:01. It may be an option if other treatments have stopped working or caused side effects.
This study tests a new drug called IMC-002 in people with advanced cancer that has not responded to standard treatment. It aims to see if the drug is safe and effective, and may be given alone or with other treatments depending on the cancer type.
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
This trial tests a new drug, MRG007, combined with other treatments for advanced colorectal cancer. The goal is to see if this combination can shrink tumors or slow the cancer's growth when standard treatments have not worked.
This trial tests a combination of two oral medications for people with advanced colorectal cancer who cannot tolerate stronger chemotherapy. The goal is to see if this gentler approach slows tumor growth and improves quality of life.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.